Aura Biosciences Inc. (AURA)
NASDAQ: AURA
· Real-Time Price · USD
6.24
-0.16 (-2.50%)
At close: Jun 17, 2025, 10:45 AM
-2.50% (1D)
| Bid | 6.24 |
| Market Cap | 386.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -94.7M |
| EPS (ttm) | -1.9 |
| PE Ratio (ttm) | -3.28 |
| Forward PE | -3.3 |
| Analyst | Buy |
| Ask | 6.28 |
| Volume | 17,987 |
| Avg. Volume (20D) | 295,669 |
| Open | 6.32 |
| Previous Close | 6.40 |
| Day's Range | 6.24 - 6.39 |
| 52-Week Range | 4.34 - 12.38 |
| Beta | 0.42 |
About AURA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AURA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AURA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts8 months ago
+14.09%
Aura Biosciences shares are trading higher after H...
Unlock content with
Pro Subscription
8 months ago
+0.39%
Aura Biosciences shares are trading higher after the company announced multiple complete clinical responses following its single low-dose administration of Bel-sar in patients with non-muscle-invasive bladder cancer in its ongoing Phase 1 trial.
